What is Eton Pharmaceuticals, Inc.'s acquisitions?

Eton Pharmaceuticals, Inc. (ETON) reported acquisitions of -$0 in Q4 2025.

How has Eton Pharmaceuticals, Inc.'s acquisitions changed year-over-year?

Eton Pharmaceuticals, Inc.'s acquisitions decreased by 100.0% year-over-year, from $7.5M to -$0.

What does acquisitions mean?

Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.

Eton Pharmaceuticals, Inc. ETON Acquisitions

Acquisitions at other companies

BioCryst PharmaceuticalsBCRX

$489.48M—

Other financials

Income statement

See full

Revenue$24.3M+40.4%

Gross profit$14.7M+49.4%

Operating income$2.4M+614%

Net income$1.6M+199%

EPS (diluted)$0.05+183%

Balance sheet

See full

Cash & equivalents$19.7M+12.9%

Total debt$31.3M+3.7%

Total equity$30.6M+25.2%

Total assets$97.7M+16.3%

Cash flow

See full

Operating cash flow$7.4M+254%

CapEx$75.0K—

Free cash flow$7.3M+251%

Valuation

See full

Market cap$930.79M+162%

Enterprise value$942.39M+156%

P/S10.7×+3.4×

Profitability

See full

Gross margin54.8%-3.7pp

Operating margin-15.1%—

Net margin-9.5%-2.7pp

FCF margin17.1%—

Returns & leverage

See full

Return on equity-34.2%+0.9pp

Debt / equity1×-0.2×

Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesGross.

The official record: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s acquisitions?: Eton Pharmaceuticals, Inc. (ETON) reported acquisitions of -$0 in Q4 2025.
How has Eton Pharmaceuticals, Inc.'s acquisitions changed year-over-year?: Eton Pharmaceuticals, Inc.'s acquisitions decreased by 100.0% year-over-year, from $7.5M to -$0.
What does acquisitions mean?: Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.